CELPROGEN
is a biotechnology company developing stem cell research and therapeutics products for regenerative medicine in cardiology, oncology, diabetes & neurology. All of Celprogen’s biological products, including stem cells, cancer stem cells, iPC’s & media including ECM’s, are manufactured and produced in the United States of America.
CELPROGEN
provides novel molecular diagnostics and therapeutic product development solutions for Biotechnology, Pharmaceutical, Invitro diagnostics and academic
partnership for drug discovery.
The Therapeutics Division
The Life Science Division
The Device Division
Has
focused its Drug Discovery efforts in the
development of Pharmaceutical agents and
Drugs in the following categories:
Cardiovascular, Diabetes, Neurological,
Renal and Metabolic disorders.
Provides research tools & solutions for assays, enzymes, antibodies,
antigens, stem cells, Tissue culture
expansion and differentiation media,
primary and established cell cultures,
tumor markers, cardiac markers, proteomic
and genomic reagents and assay systems for
life science academic and pharmaceutical
communities.
Provides novel ELISA based assay, protein array, DNA array and cellular
based assay systems that are cost
effective for Research and Invitro
diagnostics Indutstries.
Calcium
Ratio Measurement of Cardiomiocyte in Culture
- 3D Video
The therapeutic pipeline consists of the
following drug development projects in their
pre-clinical phase of development:
»
CPG23CARD
- Cholesterol lowering agent/drug.
»
CPG23DIAB
- Glucose lowering agent/drug for Type 1&2 diabetes.
»
CPG23STEM
- Adult stem cells that were trans-differentiated to
β-Islets of Langerhan Cells to produce insulin.
Pre-clinical invitro data has great promise for
cellular based therapeutics for Type 1 diabetes.
»
CPG23NEUR
- Adult stem cells that were trans-differentiated to
neuronal cells, pre-clinical invitro data has
promise for cellular based therapeutics for
neurologial disorders.
»
CPG23PANC
- Dendritic cell/peptide vaccine for pancreatic
cancer
